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Still Waiting After All These Years*







no relationshI got tired of waiting,
Wondering if you were ever coming around.
–TaylorWhen the history of the echo world is written, there will
be a long chapter on myocardial contrast echocardiography
(MCE). Conceived in the 1960s (2), reﬁned in the 1980s
(3,4,), and developed commercially in the 1990s (5), ultra-
sonic microbubbles have long held great promise for their
ability to identify obstructive coronary artery disease. The
role of ultrasound contrast agents in left ventricular opaci-
ﬁcation is well established in intensive care (6) and stress
echocardiography patients (7) and is codiﬁed in guidelines
(8), but it is the possibility of deﬁning myocardial perfusion
that sets echocardiographers’ eyes atwinkling.See page 1353There was a time in the mid to late 1990s when it was
an article of faith that MCE would soon be daily clinical
reality, threatening the existence of nuclear cardiology, with
annual markets for MCE projected to be one to two billion
dollars by 2000. This was based on solid physiologic research
(9) and promising single-center trials (10,11), some claiming
near biblical levels of accuracy (97% sensitivity and 99%
speciﬁcity on territory level) (12).
Unfortunately, the salutary results of these small trials
have never been replicated in the multicenter setting. An
early trial in 203 post-infarct patients demonstrated at best
a 31% sensitivity for identifying single-photon emission
computed tomography (SPECT) perfusion defects in the
72% of segments that were even interpretable (13).ublished in the Journal of the American College of Cardiology reﬂect the
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ollege of Cardiology.
Department of Cardiovascular Medicine, Heart and Vascular Institute,
linic Foundation, Cleveland, Ohio. Dr. Thomas has reported that he has
ips relevant to the contents of this paper to disclose.There have been two subsequent large clinical develop-
ment efforts for MCE in the United States. The ﬁrst, by
POINT BioMedical, compared their CardioSphere micro-
bubble to SPECT, using coronary angiography as a gold
standard. The trial was very carefully done, with a company
representative on-site for the imaging of every patient, and
both echo and SPECT examinations were interpreted in
a blinded fashion by multiple readers in core laboratories.
The results of the Phase III trial have unfortunately never
been published (just the Phase II trial) (14), but a contem-
porary presentation demonstrated MCE sensitivity ranging
from 63% to 75% versus 63% to 76% for SPECT and
speciﬁcity of 47% to 59% for MCE versus 53% to 76%
for SPECT, failing to meet some of the noninferiority
endpoints (J. Goldman and M. Main, personal communi-
cation, May, 2013). Also, the SPECT results themselves
were apparently poor enough to give pause to U.S. Food and
Drug Administration (FDA) reviewers. With FDA approval
not forthcoming, POINT Biomedical ultimately ceased
operations.
The second development effort involved 2 large Phase III
trials of Acusphere’s Imagify agent. The RAMP (Real-time
Assessment of Myocardial Perfusion)-1 and -2 trials (15)
studied a total of 662 patients, comparing MCE to
SPECT, using coronary angiography as the gold standard in
approximately two-thirds of the patients and clinical follow-
up used in the remainder. Multiple blinded reviewers were
used for both SPECT and MCE. While the overall accuracy
of the MCE readers (66% to 71%) was noninferior to the
SPECT results (67% to 70%), there was inconsistency
among these highly trained readers, with sensitivity ranging
from 50% to 77% and speciﬁcity ranging from 55% to 88%.
This inconsistency led to an FDA advisory panel recom-
mending against approval of Imagify in 2008, although
development efforts apparently are ongoing.
Into this troubled landscape came the largest single
multicenter study of MCE from Senior et al. (16), in this
issue of the Journal, investigating 516 patients, each of
whom underwent coronary angiography, SPECT examina-
tion, and MCE using SonoVue, a lipid-based microbubble
containing sulfur hexaﬂuoride and currently marketed in
Europe by Bracco for left ventricular opaciﬁcation. Both
SPECT and MCE were blindly interpreted by three sepa-
rate experts, while angiograms were assessed quantitatively.
Overall, 31% of patients had 70% stenosis, and, in general,
MCE yielded superior sensitivity (75% vs. 49%, p < 0.0001)
to SPECT but inferior speciﬁcity (52% vs. 81%, respectively,
p < 0.0001). Similar results were obtained in subgroup
analysis (single vs. multivessel disease, prior myocardial
infarction, proximal disease, 50% stenosis, and other
factors). These results were based on a “majority rules”
approach to the three readers, who, in general, showed only
a fair degree of agreement (k ¼ 0.37 for MCE, 0.34 for
SPECT).
How to interpret these results? The authors chose to
emphasize the positive, concluding that MCE was
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1363signiﬁcantly more sensitive than SPECT. The lower speci-
ﬁcity was in part ascribed to what the authors implied were
“false positive angiograms,” whereby the perfusion defect
resulted from nonvisualized microvascular disease. While
there may be some merit to this argument, it would have
been better supported had the investigators measured frac-
tional ﬂow reserve during catheterization. Longer follow-up
may also show the prognostic value of these ﬁndings. The
authors also emphasized the challenges of blinded test
interpretation, arguing that results should improve when
clinicians integrate patient information into their
assessments.
Nevertheless, it is hard to view these results without
pessimism. Here we are, 25þ years into commercial efforts
to develop MCE, and a well-done study, conducted by the
elite of European contrast investigators, yielded marginal
accuracy results (63% for 50% stenoses, 59% for 70%),
with little interobserver agreement among 3 highly trained
readers using well-established acquisition and interpretation
rules. The results for SPECT were similarly cautionary,
showing poor sensitivity despite 40 years of clinical devel-
opment and experience. Indeed, the evidence in all the
multicenter contrast perfusion trials has shown SPECT
accuracy generally less than 70%, with considerable inter-
observer variability. What was somewhat unusual in the
current study was that SPECT sensitivity was so much lower
than speciﬁcity, an observation that is not well explained.
The implications of these ﬁndings for the regulatory
process may be challenging. The study clearly missed one
of its primary endpoints (noninferiority of speciﬁcity for
detection of 70% stenosis), a factor that regulatory agencies
in Europe and the United States are unlikely to overlook
if this trial is used to support approval. Indeed, the hurdle
(and subsequent cost) of regulatory approval has risen
signiﬁcantly in the past 2 decades, with few new imaging
agents approved (17,18). Recent guidance from the FDA
(19) indicates that the regulatory bar has been raised well
beyond the simple diagnostic hurdle used decades ago for
thallium and technetium sestamibi: “We [FDA] recommend
that a medical imaging agent.be able to improve patient
management decisions.or improve patient outcomes..”
This is a far higher standard than that which was in place
5 decades ago when thallium-201 was undergoing FDA
scrutiny. Indeed, when New England Nuclear obtained
approval in 1977, it was for simple diagnosis and localization
of myocardial infarction (not ischemia), based largely on
patients with ﬁxed perfusion defects.(20) One cannot help
but wonder how these long-standing nuclear agents would
fare in today’s regulatory environment.
How might accuracy be improved in a subsequent MCE
trial? It starts with the microbubble itself, which must
be predictably destroyed by high mechanical index (MI)
ultrasound but provide stable, high signal-to-noise ratio
across a wide range of lower intensity imaging, properties
that depend critically on the bubble shell (21). Attenuation
can play havoc with assessment of the base of the heart, butquantitative analysis and integration of wall motion into the
interpretation might help with this. Finally, adjusting the
infusion based on weight and degree of opaciﬁcation could
provide more predictable imaging properties.
At the end of the day, however, it is worth recalling the
prophetic words of a 15-year-old editorial (22) accompa-
nying one of the ﬁrst multicenter MCE trials (13): “the
history of contrast echocardiography has been characterized
by cycles of enormous expectations and subsequent dis-
appointment.” These swings of emotion may have been
reduced in amplitude since then, as expectations are damp-
ened with every unsuccessful effort, but it is hard not to see
the MCE story as the echocardiographic equivalent of
Groundhog Day.Reprint requests and correspondence: Dr. James D. Thomas,
Department of Cardiovascular Medicine, The Cleveland Clinic
Foundation, 9500 Euclid Avenue, Desk J1-5, Cleveland,
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